Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are nucleic acid sequences capable of encoding a CAR polypeptide comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Also disclosed are vectors and cells comprising one or both of the CAR polypeptides and nucleic acid sequences capable of encoding CAR polypeptides. Also disclosed are methods of treating.

The disclosure provides methods of determining patient populations amenable or suitable for immunomodulatory treatment of disease such as cancer by measuring the relative or absolute levels of T-cell sub-populations correlated with disease such as cancer.

Tumor invasion and metastasis is accompanied by significant activations of specific proteolysis enzymes. Tumor area is known to have increased infiltration of immunoglobulins G (“IgG”), so IgG may undergo proteolysis in this area. Serine proteases usually cleave peptide bonds between positively charged amino acids lysine and arginine. Since the intact PLG molecules as well as its fragments have lysine binding sites, they can bind to damaged IgG or fragments thereof with free C-terminal lysine that can appear in a circulation after proteolysis in the malignant tumor area. In the present invention we demonstrated the increased binding of damaged IgG or fragments thereof with free C-terminal lysine to fragments of PLG in samples from patients with breast cancer, ovarian cancer, lung cancer, colorectal cancer, prostate cancer vs. samples from healthy donors, and thus we proposed a novel diagnostic method.

The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Described herein and RNA aptamers that specifically bind to tumor-infiltrating myeloid cells and uses thereof.

The present invention generally relates to pharmacokinetic and pharmacodynamics markers for cancer therapeutic regimens and methods of treating cancer. Oncolytic virus probes that comprise a nucleic acid encoding soluble interferon beta (IFNβ) and methods for use thereof are provided.

Methods are provided for determining prognosis of multiple myeloma in a patient by measuring expression of BCMA in a sample. Also provided are methods for treating multiple myeloma by measuring expression of BCMA in a sample and administering an effective amount of an antigen binding protein that binds BCMA. Also provided are kits for measuring BCMA expression in a sample.

A method of identifying cancer patients who would be responsive to bladder sparing surgery plus chemoradiation therapy or cystectomy using expression of MRE11 in a nuclear to cytoplasmic ratio is presented.

The present invention provides methods and compositions for treating a cancer, methods for increasing an immune response against a tumor, methods for treating an autoimmune disease, and methods for decreasing an inflammation response in a subject in need thereof by modulating the expression and/or activity of Siglec 15 and/or its binding ligands.